Abstract: A pixel structure, a driving method thereof and a display device are disclosed. The pixel structure includes: a pixel circuit and a plurality of light emitting devices; the pixel circuit has a plurality of display periods, each display period includes: a first reset stage, a data write stage, a second reset stage and a light emitting stage, the driving method includes: in the second reset stage, providing a valid level signal to at least one second reset line to cause the corresponding second reset sub-circuit to write a voltage on the initialization signal line into a first electrode of the light emitting device; in the light emitting stage, providing a valid level signal to a first light emitting control line and providing a valid level signal to at least one second light emitting control line.

Abstract: The present invention provides an optimization method and system for minimizing network energy consumption based on traffic grooming. The method includes: generating a set of service requests in an elastic optical network, and calculating a reachable node set of shortest paths from source to destination nodes for each service request; establishing a virtual reachable path in the reachable node set of shortest paths; and establishing a target function of an integer linear programming model of the minimizing network energy consumption, and sequentially determining whether a bandwidth capacity constraint of a single spectrum slot, a path uniqueness constraint, a spectrum allocation constraint, and an optical regenerator quantity constraint are satisfied, where if all constraints are satisfied, the service request is successfully established, or if any of the constraints is not satisfied, the service request fails to be established. The present invention helps to improve the energy efficiency of service requests.

Abstract: The present disclosure provides a display substrate, a chip-on-film, a display apparatus and methods for manufacturing them. The display apparatus includes: a base substrate; a bonding structure disposed on the base substrate; and a chip-on-film COF, wherein the COF and a side of the bonding structure that is away from the base substrate are clamped with each other, and the COF is bonded to the side of the bonding structure that is away from the base substrate; wherein when the COF and the bonding structure are bonded, the COF contacts both a first surface and a second surface of the bonding structure at the side of the bonding structure that is away from the base substrate, wherein the first surface is parallel to the base substrate, and the second surface is at an angle with the first surface.

Abstract: A flexible display panel and a preparation method therefor, a display apparatus, and a tiled display apparatus. The flexible display panel is provided with a display area and a peripheral area located on the periphery of the display area, the peripheral area comprising at least one bent area and a folded area located on a side of each bent area away from the display area. The flexible display panel comprises: a flexible substrate and a frame circuit that is disposed on the flexible substrate and is located in the peripheral area, at least a portion of the frame circuit being located in the folded area. The portion of the flexible display panel that is located in the folded area is configured to, by means of the portion located in the bent area, be folded in the direction away from the display side of the flexible display panel.

Abstract: The disclosure discloses a display panel, a preparation method thereof and a display device. The display panel includes: a base substrate, a plurality of light emitting devices located on the base substrate, and a film packaging structure located on a side, away from the base substrate, of the light emitting devices, wherein the film packaging structure includes a first inorganic packaging film on the side, away from the base substrate, of the light emitting devices, a second inorganic packaging film on the side, away from the light emitting devices, of the first inorganic packaging film, and an organic packaging film between the first inorganic packaging film and the second inorganic packaging film; and the first inorganic packaging film is provided with convex structures at gaps among the light emitting devices, and the organic packaging film is disconnected at the convex structures.

Abstract: A pixel structure, a driving method thereof and a display device are disclosed. The pixel structure includes: a pixel circuit and a plurality of light emitting devices; the pixel circuit has a plurality of display periods, each display period includes: a first reset stage, a data write stage, a second reset stage and a light emitting stage, the driving method includes: in the second reset stage, providing a valid level signal to at least one second reset line to cause the corresponding second reset sub-circuit to write a voltage on the initialization signal line into a first electrode of the light emitting device; in the light emitting stage, providing a valid level signal to a first light emitting control line and providing a valid level signal to at least one second light emitting control line.

Abstract: The present invention provides an energy consumption optimization method and system for a radio access spectrum-flexible optical network. The method includes: acquiring a set of traffic demands; obtaining the minimum number of occupied remote radio heads (RRH) and the minimum number of occupied baseband unit (BBU) ports of the traffic demands based on a traffic grooming algorithm; and solving an objective function based on the constraints of the objective function of traffic grooming energy consumption optimization, to implement transmission for the traffic demands.

Abstract: The present invention provides a protection method and system in flexible bandwidth optical networks with multi-core fiber. The method includes steps of: selecting an appropriate working path for a connection request, and selecting a working core as a transmission channel on the working path; allocating, on the selected working path and working core, a spectrum resource that satisfies spectral continuity, spectral consistency, and a crosstalk threshold constraint; selecting, for the connection request, a dedicated protection path that does not intersect a link of the working path, and selecting a protection core as a transmission channel on the protection path; and finally, allocating, on the selected protection path and protection core, the spectrum resource that satisfies the spectral continuity, the spectral consistency, and the crosstalk threshold constraint.

Abstract: The present invention provides a protection method and system in flexible bandwidth optical networks with multi-core fiber. The method includes steps of: selecting an appropriate working path for a connection request, and selecting a working core as a transmission channel on the working path; allocating, on the selected working path and working core, a spectrum resource that satisfies spectral continuity, spectral consistency, and a crosstalk threshold constraint; selecting, for the connection request, a dedicated protection path that does not intersect a link of the working path, and selecting a protection core as a transmission channel on the protection path; and finally, allocating, on the selected protection path and protection core, the spectrum resource that satisfies the spectral continuity, the spectral consistency, and the crosstalk threshold constraint.

Abstract: Embodiments of the present disclosure provide a display substrate, including: a base substrate; a light emitting device on the base substrate; an encapsulating layer on the base substrate and configured to encapsulate the light emitting device; and an anti-vibration layer on the base substrate. An orthographic projection of the anti-vibration layer on the base substrate has no overlap with an orthographic projection of the light emitting device on the base substrate. The orthographic projection of the anti-vibration layer on the base substrate has an overlap with an orthographic projection of the encapsulating layer on the base substrate, and the overlap is smaller than the orthographic projection of the anti-vibration layer on the base substrate in area. The embodiments of the present disclosure further provide a manufacturing method of a display substrate, a display module, and a display device.

Abstract: The present invention provides an energy consumption optimization method and system for a radio access spectrum-flexible optical network. The method includes: acquiring a set of traffic demands; obtaining the minimum number of occupied remote radio heads (RRH) and the minimum number of occupied baseband unit (BBU) ports of the traffic demands based on a traffic grooming algorithm; and solving an objective function based on the constraints of the objective function of traffic grooming energy consumption optimization, to implement transmission for the traffic demands.

Abstract: The disclosure discloses a display panel, a preparation method thereof and a display device. The display panel includes: a base substrate, a plurality of light emitting devices located on the base substrate, and a film packaging structure located on a side, away from the base substrate, of the light emitting devices, wherein the film packaging structure includes a first inorganic packaging film on the side, away from the base substrate, of the light emitting devices, a second inorganic packaging film on the side, away from the light emitting devices, of the first inorganic packaging film, and an organic packaging film between the first inorganic packaging film and the second inorganic packaging film; and the first inorganic packaging film is provided with convex structures at gaps among the light emitting devices, and the organic packaging film is disconnected at the convex structures.

Abstract: A compound for treating a disease, in particular cancer like non-small cell lung cancer, exceptionally inhibits activity of oncogenic ALK kinase. Compositions, particularly pharmaceutical compositions, are provided comprising this compound. Methods for targeting cancer cells harboring an abnormality in the ALK gene are also The compound for treating a disease has certain structural elements, namely a tricyclic, more specifically heterocyclic, backbone as the core part of the compound at least one highly electronegative atom in form of a tertiary amine attached to the backbone via an at most 6-membered linking group with a terminal highly electronegative atom in form of a nitrogen as secondary amine, and a further hydrophobic moiety fused to the backbone. The structural components allow for an advantageous interaction with the ALK kinase domain. The compound therefor represents a highly promising treatment option for patients in particular those bearing ALK-dependent non-small cell lung cancer.

Abstract: The administration of a compound advantageously efficacious as ROS1 inhibitor and its effect on subjects with cancer includes administering a compound having certain structural components such as a quinoline moiety in the backbone and at least one tertiary amine containing moiety in a side chain as well as heteroatoms, in particular oxygen atoms, present in the backbone and the side chain for treating a subject suffering from a disease such as cancer. The presence of such structural components allows for an advantageous interaction with the ROS1 kinase domain, in particular with the hinge region. The administered compounds represent a highly promising opportunity in particular for patients bearing ROS1-dependent cancer. A method for targeting tumor cells harboring an abnormality in ROS1 gene includes contacting a cell with compounds of the present invention as well as pharmaceutical compositions comprising such compounds.

Abstract: A compound for treating a disease, in particular cancer like non-small cell lung cancer, exceptionally inhibits activity of oncogenic ALK kinase. Compositions, particularly pharmaceutical compositions, are provided comprising this compound. Methods for targeting cancer cells harboring an abnormality in the ALK gene are also The compound for treating a disease has certain structural elements, namely a tricyclic, more specifically heterocyclic, backbone as the core part of the compound at least one highly electronegative atom in form of a tertiary amine attached to the backbone via an at most 6-membered linking group with a terminal highly electronegative atom in form of a nitrogen as secondary amine, and a further hydrophobic moiety fused to the backbone. The structural components allow for an advantageous interaction with the ALK kinase domain. The compound therefor represents a highly promising treatment option for patients in particular those bearing ALK-dependent non-small cell lung cancer.

Abstract: The present invention provides methods for treatment of a RAS-positive disease, in particular KRAS-positive non-small cell lung cancer as well as a method for potentiating the apoptotic activity of a PDE? inhibitor by combining the PDE? inhibitor with a direct autophagy inhibitor. The PDE? inhibitor is preferably, but not exclusively, deltarasin, and the direct autophagy inhibitor is in particular 3-methyladenine. Further provided by the present invention are a kit and a pharmaceutical composition comprising the PDE? inhibitor and a direct autophagy inhibitor. The methods of the present invention in particular provide a new treatment option for RAS-positive diseases such as KRAS-positive non-small cell lung cancer allowing for an increased apoptotic activity of the PDE? inhibitor by simultaneously blocking its “tumor protective” autophagy.

Abstract: A compound suitable for treating cancer, in particular NSCLC, inhibits activity of oncogenic ROS1 kinase and ALK kinase. The compound has certain structural components such as a quinoline moiety in the backbone and at least one phenyl-containing moiety in a side chain with a hydrophobic substituent attached to the backbone via an up to 6-membered linking group as well as a further hydrophobic moiety. The presence of the structural components allows for an advantageous interaction with the ROS1 kinase domain and, further, with the ALK kinase domain. Hence, said compound represents a highly promising opportunity for patients bearing ROS1- or ALK-dependent cancer. A composition, in particular a pharmaceutical composition, includes the compound. A method for targeting cancer cells harboring an abnormality in ROS1 gene or ALK gene includes contacting a cell with the compound.

Abstract: The present invention relates to the administration of a novel compound advantageously efficacious as PDE? inhibitor and its effects on subjects with cancer. More specifically, the present invention is directed to a method for administering a compound having favorable geometric properties for interacting with the PDE? prenyl-binding pocket, namely has certain structural components such as a three-cyclic backbone and at least one benzoyl-moiety in a side chain having at least two substituents containing highly electronegative atoms and being linked to the backbone via an aliphatic chain, for treating a subject suffering from a disease such as cancer, in particular non-small-cell lung cancer. The presence of said structural components particularly contributes to an advantageous interaction with PDE?, in particular with amino acids deep in the binding pocket.

Abstract: The administration of a compound advantageously efficacious as ROS1 inhibitor and its effect on subjects with cancer includes administering a compound having certain structural components such as a quinoline moiety in the backbone and at least one tertiary amine containing moiety in a side chain as well as heteroatoms, in particular oxygen atoms, present in the backbone and the side chain for treating a subject suffering from a disease such as cancer. The presence of such structural components allows for an advantageous interaction with the ROS1 kinase domain, in particular with the hinge region. The administered compounds represent a highly promising opportunity in particular for patients bearing ROS1-dependent cancer. A method for targeting tumor cells harboring an abnormality in ROS1 gene includes contacting a cell with compounds of the present invention as well as pharmaceutical compositions comprising such compounds.

Abstract: The present invention provides a compound that inhibits activity of oncogenic ROS1, a composition comprising said compound. The present invention also provides the use of said composition for treating cancer.